Intracoronary Stem Cell Transplantation in Acute Myocardial Infarction

Fernández-Avilés, Francisco; Román, José Alberto San; Frade, Javier García; Valdés, Mariano; Sánchez, Abraham; Fuente, Luis de la; Peñarrubia, María Jesús; Fernández, María E.; Tejedor, Paula; Durán, Juan Manuel; Hernández, Carlos; Sanz, Ricardo; Sancho, Javier García

doi:10.1016/s1885-5857(06)60137-0

Cited by 23 publications

(14 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The results show heart function improvement after stem cells transplantation [1][2][3][4][5][6][7][8][9][10][11]. However, It remains unclear which stem cell(s) can contribute to these effects on the myocardium, and whether they do so by trans-differentiation or cell fusion [12].…”

Section: Introductionmentioning

confidence: 99%

Engraftment of pre-differentiated stem cells into cardiomyocytes in an animal model of ischemic cardiopathy

González‐Garza

Alcaraz²,

Gonzalez-Jara³

et al. 2014

SCD

View full text Add to dashboard Cite

Stem cell therapy for cardiac infarct regeneration has been widely used in clinical research. Despite the fact that important advances in this field have been reached, the observed recovery does not demonstrate new cardiac muscle formation. Benefits have been observed due to an improvement in neovascularisation. The main objective of this study was to determine if predifferentiated stem cells into cells of myocardic lineage are capable of engraftment in animal models with induced cardiac infarct and are capable of truly differentiating into myocardiocytes. Bone marrow rat stem cells were predifferentiated with 5-AZ. After 4 weeks, pre-differentiated stem cells express muscarinic 1, 2 and β adrenergic 2 receptors. Also, proteins such as sarcomeric α-actin, cardiac myosin heavy chain, desmin and vimentin were detected by immunocytochemistry. Cells were transplanted intracardialy in an ischemic cardiac rat model. Pre-differentiated or non differentiated cells were transplanted after 4 weeks post infarct induction. Histopathology of the hearts was made 2 weeks after cell transplantation. Typical granulated tissue, scare formation and neovascularisation were observed in both groups. However, in those hearts from rats inoculated with pre-differentiated cells many appeared atypical and were α-actin sarcomeric positive. These events suggest that pre-differentiated cells conserve some muscle characteristic traits in situ that at least last for two weeks after transplantation.

show abstract

Section: Introductionmentioning

confidence: 99%

Engraftment of pre-differentiated stem cells into cardiomyocytes in an animal model of ischemic cardiopathy

González‐Garza

Alcaraz²,

Gonzalez-Jara³

et al. 2014

SCD

View full text Add to dashboard Cite

show abstract

“…Encouraging results from twenty patients transplanted with bone marrow-derived mononuclear cells was also reported by Aviles et al [89,90]. In contrast to the previous reports, Kuethe et al did not reveal any significant difference regarding left ventricular function or coronary flow reserve at three and twelve-month follow-up [91].…”

Section: Intracoronary Deliverymentioning

confidence: 72%

Adult bone marrow-derived stem cells and the injured heart: just the beginning?

Dimarakis

Habib

Gordon

2005

European Journal of Cardio-Thoracic Surgery

View full text Add to dashboard Cite

Coronary artery disease leading to ischaemia of the human myocardium is one of the chief causes of morbidity and mortality in the western world. Cellular transplantation has recently been proposed as a novel alternative treatment modality. Adult bone marrow-derived autologous cells are one of the key cell types under investigation in both the experimental and clinical setting. A range of theories has been proposed with regard to the observed myocardial function improvement in both human and animal studies. A concerted interest in scientific questions needs to be constructed on the regenerative information made available throughout the last years. It is only now that we begin to fully understand this fast growing body of research and how it may have wide ranging implications for the treatment of ischemic heart disease.

show abstract

“…The types of bone-marrow-derived stem cells that had been used in clinical practice are: bone-marrow-derived mononuclear cells, [8][9][10][11]13,[15][16][20][21][22][23]25,26,[28][29][30] bone-marrowderived nucleated cells, 19,24 bone-marrow-derived mesenchymal cells, 12,14 bone-marrow-derived endothelial progenitor cells, [9][10][11]14,18,[30][31][32] and isolated CD133þ 17 and CD34þ progenitors (Tables 1 to 3).…”

Section: -32mentioning

confidence: 99%

Percutaneous bone-marrow-derived cell transplantation: clinical observations

Sánchez¹,

Villa²,

Román³

et al. 2006

European Heart Journal Supplements

View full text Add to dashboard Cite

Different types and routes of stem cell delivery have been used in clinical practice to repair infarcted or ischaemic myocardium. Of these, percutaneous administration of bone-marrow-derived progenitors represents the most optimal method to date, as it allows the evaluation of the cells' effects independent of revascularization and the application of multiple administrations over time. Two different percutaneous catheter-based methods have been used in clinical trials to deliver bone-marrow-derived stem cells: intracoronary infusion and transendomyocardial delivery through a left ventricle catheter. Despite the clinical scenarios investigated (acute myocardial infarction, chronic ischaemia with no revascularization option, and ischaemic cardiomyopathy), in general percutaneous bone-marrow-derived stem cell therapy is feasible, relatively safe (with unresolved concerns regarding arrhythmias, restenosis, and atherosclerosis progresion), and could exert a benefit upon ventricular function and perfusion. At this point, intermediate-size, randomized trials are aimed to well establish the efficacy of this therapy that analyses surrogate endpoints: either perfusion or left ventricular function based on the clinical scenario tested.

show abstract

Intracoronary Stem Cell Transplantation in Acute Myocardial Infarction

Cited by 23 publications

References 22 publications

Engraftment of pre-differentiated stem cells into cardiomyocytes in an animal model of ischemic cardiopathy

Engraftment of pre-differentiated stem cells into cardiomyocytes in an animal model of ischemic cardiopathy

Adult bone marrow-derived stem cells and the injured heart: just the beginning?

Percutaneous bone-marrow-derived cell transplantation: clinical observations

Contact Info

Product

Resources

About